Literature DB >> 34166073

Cerebral Cavernous Malformation: From Mechanism to Therapy.

Daniel A Snellings1, Courtney C Hong2, Aileen A Ren2, Miguel A Lopez-Ramirez3,4, Romuald Girard5, Abhinav Srinath5, Douglas A Marchuk1, Mark H Ginsberg3, Issam A Awad5, Mark L Kahn2.   

Abstract

Cerebral cavernous malformations are acquired vascular anomalies that constitute a common cause of central nervous system hemorrhage and stroke. The past 2 decades have seen a remarkable increase in our understanding of the pathogenesis of this vascular disease. This new knowledge spans genetic causes of sporadic and familial forms of the disease, molecular signaling changes in vascular endothelial cells that underlie the disease, unexpectedly strong environmental effects on disease pathogenesis, and drivers of disease end points such as hemorrhage. These novel insights are the integrated product of human clinical studies, human genetic studies, studies in mouse and zebrafish genetic models, and basic molecular and cellular studies. This review addresses the genetic and molecular underpinnings of cerebral cavernous malformation disease, the mechanisms that lead to lesion hemorrhage, and emerging biomarkers and therapies for clinical treatment of cerebral cavernous malformation disease. It may also serve as an example for how focused basic and clinical investigation and emerging technologies can rapidly unravel a complex disease mechanism.

Entities:  

Keywords:  central nervous system; endothelial cells; hemorrhage; stroke; vascular malformations

Mesh:

Year:  2021        PMID: 34166073      PMCID: PMC8922476          DOI: 10.1161/CIRCRESAHA.121.318174

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   23.213


  184 in total

1.  Soluble thrombomodulin: a sign of bad times.

Authors:  Shinichiro Kurosawa; Deborah J Stearns-Kurosawa; Gary T Kinasewitz
Journal:  Crit Care Med       Date:  2008-03       Impact factor: 7.598

Review 2.  Cytoprotective-selective activated protein C therapy for ischaemic stroke.

Authors:  Laurent O Mosnier; Berislav V Zlokovic; John H Griffin
Journal:  Thromb Haemost       Date:  2014-09-18       Impact factor: 5.249

3.  Cerebral cavernous malformation protein CCM1 inhibits sprouting angiogenesis by activating DELTA-NOTCH signaling.

Authors:  Joycelyn Wüstehube; Arne Bartol; Sven S Liebler; René Brütsch; Yuan Zhu; Ute Felbor; Ulrich Sure; Hellmut G Augustin; Andreas Fischer
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-24       Impact factor: 11.205

4.  Symptomatic Brain Hemorrhages from Cavernous Angioma After Botulinum Toxin Injections, a Role of TLR/MEKK3 Mechanism? Case Report and Review of the Literature.

Authors:  Janne Koskimäki; Dongdong Zhang; Julián Carrión-Penagos; Romuald Girard; Kristina Piedad; Sean P Polster; Seán Lyne; Agnieszka Stadnik; Issam A Awad
Journal:  World Neurosurg       Date:  2020-01-07       Impact factor: 2.104

5.  Dynamic regulation of the cerebral cavernous malformation pathway controls vascular stability and growth.

Authors:  Xiangjian Zheng; Chong Xu; Annie O Smith; Amber N Stratman; Zhiying Zou; Benjamin Kleaveland; Lijun Yuan; Chuka Didiku; Aslihan Sen; Xi Liu; Nicolas Skuli; Alexander Zaslavsky; Mei Chen; Lan Cheng; George E Davis; Mark L Kahn
Journal:  Dev Cell       Date:  2012-08-14       Impact factor: 12.270

6.  Cavernomas in children with brain tumors: a late complication of radiotherapy.

Authors:  J F Martínez-Lage; I de la Fuente; J Ros de San Pedro; J L Fuster; M A Pérez-Espejo; M T Herrero
Journal:  Neurocirugia (Astur)       Date:  2008-02       Impact factor: 0.553

7.  Radiation-induced cavernous hemangiomas of the brain: a late effect predominantly in children.

Authors:  Stefan Heckl; Alfred Aschoff; Stefan Kunze
Journal:  Cancer       Date:  2002-06-15       Impact factor: 6.860

8.  Familial cavernous angiomas.

Authors:  J M Bicknell; T J Carlow; M Kornfeld; J Stovring; P Turner
Journal:  Arch Neurol       Date:  1978-11

9.  Novel Murine Models of Cerebral Cavernous Malformations.

Authors:  Matthew R Detter; Robert Shenkar; Christian R Benavides; Catherine A Neilson; Thomas Moore; Rhonda Lightle; Nicholas Hobson; Le Shen; Ying Cao; Romuald Girard; Dongdong Zhang; Erin Griffin; Carol J Gallione; Issam A Awad; Douglas A Marchuk
Journal:  Angiogenesis       Date:  2020-07-24       Impact factor: 9.596

10.  Cerebral cavernous malformations arise from endothelial gain of MEKK3-KLF2/4 signalling.

Authors:  Zinan Zhou; Alan T Tang; Weng-Yew Wong; Sharika Bamezai; Lauren M Goddard; Robert Shenkar; Su Zhou; Jisheng Yang; Alexander C Wright; Matthew Foley; J Simon C Arthur; Kevin J Whitehead; Issam A Awad; Dean Y Li; Xiangjian Zheng; Mark L Kahn
Journal:  Nature       Date:  2016-03-30       Impact factor: 49.962

View more
  9 in total

1.  Circulating Plasma miRNA Homologs in Mice and Humans Reflect Familial Cerebral Cavernous Malformation Disease.

Authors:  Abhinav Srinath; Ying Li; Romuald Girard; Issam A Awad; Sharbel G Romanos; Bingqing Xie; Chang Chen; Yan Li; Thomas Moore; Dehua Bi; Je Yeong Sone; Rhonda Lightle; Nick Hobson; Dongdong Zhang; Janne Koskimäki; Le Shen; Sara McCurdy; Catherine Chinhchu Lai; Agnieszka Stadnik; Kristina Piedad; Julián Carrión-Penagos; Abdallah Shkoukani; Daniel Snellings; Robert Shenkar; Dinanath Sulakhe; Yuan Ji; Miguel A Lopez-Ramirez; Mark L Kahn; Douglas A Marchuk; Mark H Ginsberg
Journal:  Transl Stroke Res       Date:  2022-06-17       Impact factor: 6.829

Review 2.  Genetics of brain arteriovenous malformations and cerebral cavernous malformations.

Authors:  Hiroki Hongo; Satoru Miyawaki; Yu Teranishi; Daiichiro Ishigami; Kenta Ohara; Yu Sakai; Daisuke Shimada; Motoyuki Umekawa; Satoshi Koizumi; Hideaki Ono; Hirofumi Nakatomi; Nobuhito Saito
Journal:  J Hum Genet       Date:  2022-07-13       Impact factor: 3.755

Review 3.  Rapamycin in Cerebral Cavernous Malformations: What Doses to Test in Mice and Humans.

Authors:  Matthew J Hagan; Robert Shenkar; Abhinav Srinath; Sharbel G Romanos; Agnieszka Stadnik; Mark L Kahn; Douglas A Marchuk; Romuald Girard; Issam A Awad
Journal:  ACS Pharmacol Transl Sci       Date:  2022-04-25

4.  Endothelial k-RasV12 Expression Induces Capillary Deficiency Attributable to Marked Tube Network Expansion Coupled to Reduced Pericytes and Basement Membranes.

Authors:  Zheying Sun; Scott S Kemp; Prisca K Lin; Kalia N Aguera; George E Davis
Journal:  Arterioscler Thromb Vasc Biol       Date:  2021-12-09       Impact factor: 8.311

Review 5.  Cerebral Cavernous Malformation: Immune and Inflammatory Perspectives.

Authors:  Tianqi Tu; Zhenghong Peng; Jian Ren; Hongqi Zhang
Journal:  Front Immunol       Date:  2022-06-30       Impact factor: 8.786

6.  Simplex cerebral cavernous malformations with MAP3K3 mutation have distinct clinical characteristics.

Authors:  Ran Huo; Jie Wang; Ying-Fan Sun; Jian-Cong Weng; Hao Li; Yu-Ming Jiao; Hong-Yuan Xu; Jun-Ze Zhang; Shao-Zhi Zhao; Qi-Heng He; Shuo Wang; Ji-Zong Zhao; Yong Cao
Journal:  Front Neurol       Date:  2022-08-26       Impact factor: 4.086

Review 7.  Atlas of Nervous System Vascular Malformations: A Systematic Review.

Authors:  Carlos Castillo-Rangel; Gerardo Marín; Karla Aketzalli Hernandez-Contreras; Cristofer Zarate-Calderon; Micheel Merari Vichi-Ramirez; Wilmar Cortez-Saldias; Marco Antonio Rodriguez-Florido; Ámbar Elizabeth Riley-Moguel; Omar Pichardo; Osvaldo Torres-Pineda; Helena G Vega-Quesada; Ramiro Lopez-Elizalde; Jaime Ordoñez-Granja; Hugo Helec Alvarado-Martinez; Luis Andrés Vega-Quesada; Gonzalo Emiliano Aranda-Abreu
Journal:  Life (Basel)       Date:  2022-08-07

8.  Vascular and Lymphatic Malformations: Perspectives From Human and Vertebrate Studies.

Authors:  Harish P Janardhan; Sherin Saheera; Roy Jung; Chinmay M Trivedi
Journal:  Circ Res       Date:  2021-06-24       Impact factor: 23.213

9.  Elevated proportion of TLR2- and TLR4-expressing Th17-like cells and activated memory B cells was associated with clinical activity of cerebral cavernous malformations.

Authors:  Camilla Castro; Hugo A A Oyamada; Marcos Octávio S D Cafasso; Lana M Lopes; Clarice Monteiro; Priscila M Sacramento; Soniza Vieira Alves-Leon; Gustavo da Fontoura Galvão; Joana Hygino; Jorge Paes Barreto Marcondes de Souza; Cleonice A M Bento
Journal:  J Neuroinflammation       Date:  2022-02-02       Impact factor: 8.322

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.